📬 Breast Cancer Intelligence Digest — Week 2026-W29

New this week: a Trop-2 ADC meta-analysis ties PFS benefit to Trop-2-high tumors, racial disparities persist in HER2+ ADC-treated MBC, JCOG1017/PRIM-BC finds primary tumor resection does not improve OS, OPTIMAL confirms oral paclitaxel non-inferiority, and FDA approves T-DXd in HER2+ early breast cancer.

⚡ TL;DR

📄 Publications

Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis. — ADC-T2 improved PFS in both Trop-2-high (HR 0.34) and Trop-2-low (HR 0.63) subgroups

🐦 Twitter / 🦋 Bluesky

RxPONDER AMH analysis: ovarian reserve markers not yet ready to tailor adjuvant therapy — High AMH predicted greater chemotherapy benefit and low AMH limited additional benefit, but not ready for routine use
JCOG1017/PRIM-BC: primary tumor resection does not improve overall survival in de novo stage IV disease — Among 407 patients, primary tumor resection did not significantly improve OS versus systemic therapy alone (75 vs 69 months)
Extending ovarian-suppression-based endocrine therapy beyond 5 years in high-risk premenopausal HR+ disease — 37% lower risk of invasive recurrence (HR 0.63) and 51% lower risk of distant recurrence (HR 0.49)
OPTIMAL: oral paclitaxel (DHP107) non-inferior to weekly IV paclitaxel in HER2-negative metastatic disease — Oral paclitaxel DHP107 is non-inferior to weekly IV paclitaxel with less neuropathy and no infusion
Trop-2 ADC meta-analysis: benefit greatest in Trop-2-high tumors, and confined to Trop-2-high in HR+/HER2- disease — Meta-analysis of randomized trials shows Trop-2 ADCs provide the greatest PFS benefit in Trop-2-high MBC

Full details below ↓

📄 What's Being Published

Manuscripts:

Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis. — Buonaiuto Roberto et al., J Natl Cancer Inst

Five randomized trials (ASCENT, TROPiCS-02, EVER-132-002, OptiTROP-Breast01, and TROPION-Breast01) including 1,879 patients treated with ADC-T2 or chemotherapy were analyzed. ADC-T2 significantly improved PFS compared to chemotherapy in both Trop-2-high (HR 0.34, 95% CI 0.20–0.57) and Trop-2-low (HR 0.63, 0.50–0.79) subgroups. In HR+/HER2− mBC, a significant PFS benefit was observed only in the Trop-2-high subgroup (HR 0.56, 0.47 to 0.68, p < 0.001).

Clinical bottom line: Trop-2 ADCs deliver PFS benefit across expression levels but the gain is greatest in Trop-2-high tumors, and in HR+/HER2− disease the benefit is confined to Trop-2-high, arguing for standardized Trop-2 assays.

Read full article →

Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates. — Shah Zunairah et al., J Natl Cancer Inst

In a cohort of 7,462 HER2+ MBC patients, five-year OS was highest among Asian (89.9%) and Hispanic (86.3%) patients, followed by non-Hispanic White (84.0%) and Black patients (80.3%) (P < .001). Compared with non-Hispanic White patients, Black patients experienced significantly worse OS (adjusted HR, 1.22; 95% CI, 1.03 to 1.45; P=.03).

Clinical bottom line: Among HER2+ MBC patients receiving HER2-directed ADCs, Black patients had persistently inferior survival despite effective therapy, exposing inequities that treatment advances alone have not closed.

Read full article →

SERD Wars: Clinical Integration of Emerging Endocrine-Directed and Precision Therapies in Breast Cancer. — Lloyd Maxwell R et al., JCO Oncol Pract

Pivotal trials demonstrate that oral selective estrogen receptor degraders (SERDs) and other novel ER-directed agents enhance anticancer activity, particularly for ESR1-mutant disease.

Clinical bottom line: With multiple oral SERDs and biomarker-guided combinations entering practice, their optimal sequencing and interchangeability remain unresolved, and ctDNA monitoring for acquired ESR1 mutations may enable earlier switching.

Read full article →

Beyond amplification: precision approaches to targeting HER2. — Lloyd Maxwell R et al., Clin Cancer Res

HER2-directed tyrosine kinase inhibitor combinations with trastuzumab represent an emerging strategy for hormone receptor-negative or -positive metastatic breast cancer with activating HER2 mutations.

Clinical bottom line: For HER2-mutant breast cancer, TKI-plus-trastuzumab combinations paired with correlative genomics can reveal response patterns and acquired resistance, keeping precision refinement a priority.

Read full article →

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program. — Domènech Heura et al., NPJ Precis Oncol

HRD was more frequent in high-grade ovarian cancer (52%) than in metastatic breast cancer (12%). Longitudinal ctDNA sequencing revealed BRCA1/BRCA2 reversion mutations in >30% of post-PARPi mBC samples, which were associated with poor response to subsequent platinum therapy.

Clinical bottom line: Complementary HRD biomarkers in tissue and liquid biopsy detect deficiency missed by mutation testing and reveal BRCA reversion in over 30% of post-PARPi breast samples, supporting integrated testing to guide and monitor PARPi use.

Read full article →

Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD. — Masuda Norikazu et al., Breast Cancer Res Treat

Progression-free survival was similar for eribulin versus docetaxel (14.0 vs. 13.1 months; HR 0.94, 95% CI 0.74–1.21). Median time to QoL deterioration was longer with eribulin versus docetaxel (7.8 vs. 4.7 months).

Clinical bottom line: When combined with dual HER2 blockade first-line, eribulin matches docetaxel or paclitaxel on efficacy while preserving quality of life longer, offering a taxane alternative.

Read full article →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

RxPONDER AMH analysis: ovarian reserve markers not yet ready to tailor adjuvant therapy

The RxPONDER AMH analysis indicated that high AMH predicted greater chemotherapy benefit while low AMH predicted limited additional benefit, yet the accompanying editorial concludes there is at present no established clinical utility for routine use of ovarian reserve markers. The central debate is whether AMH and related markers should factor into adjuvant chemotherapy decisions for premenopausal HR+ patients now, or whether prospective validation must come first.

Discussed by: @K_Yadavir, @DFCI_BreastOnc

→ View representative tweet

JCOG1017/PRIM-BC: primary tumor resection does not improve overall survival in de novo stage IV disease

Among 407 patients receiving systemic therapy, primary tumor resection did not significantly improve overall survival compared with systemic therapy alone (75 vs. 69 months). Surgery did markedly improve local relapse-free survival and showed potential benefit in premenopausal patients and those with single-organ metastases, framing the question of which patients, if any, should be offered resection for local control absent a survival benefit.

Discussed by: @OncoAlert, @stolaney1

→ View representative tweet

Extending ovarian-suppression-based endocrine therapy beyond 5 years in high-risk premenopausal HR+ disease

Extended follow-up from SOFT/TEXT showed a 37% lower risk of invasive recurrence (HR 0.63; P=0.0135) and a 51% lower risk of distant recurrence (HR 0.49; P=0.0033) with ovarian function suppression-based therapy. At 15 years, exemestane plus OFS is considered the priority regimen for high-risk premenopausal HR+ disease, while treatment de-escalation remains reasonable for lower-risk patients—leaving clinicians to weigh whether extended endocrine therapy justifies its added burden in patients already disease-free after 5 years.

Discussed by: @ChandrakanthMv, @Dr_Oncologista

→ View representative tweet

OPTIMAL: oral paclitaxel (DHP107) non-inferior to weekly IV paclitaxel in HER2-negative metastatic disease

The OPTIMAL trial established that oral paclitaxel (DHP107) is non-inferior to weekly IV paclitaxel in HER2− metastatic breast cancer, with less neuropathy and no requirement for infusion; the agent is now MFDS-approved in Korea on a weekly schedule. The question for oncologists is whether an oral, infusion-free taxane with a reduced neuropathy burden could shift chemotherapy delivery practice in HER2-negative metastatic disease.

Discussed by: @sbkim712, @kazuki_nozawa

→ View representative tweet

Trop-2 ADC meta-analysis: benefit greatest in Trop-2-high tumors, and confined to Trop-2-high in HR+/HER2− disease

A meta-analysis of randomized trials shows that Trop-2 ADCs provide the greatest PFS benefit in Trop-2-high MBC. In HR+/HER2− mBC specifically, a significant PFS benefit was observed only in the Trop-2-high subgroup (HR 0.56, 0.47 to 0.68, p < 0.001), sharpening the debate over whether standardized Trop-2 assays should become routine to select patients for Trop-2-directed ADCs in this subtype.

Discussed by: @OncoAlert, @OncLive

→ View representative tweet

KEYNOTE-355 post-hoc: responders can pause chemotherapy yet maintain survival on pembrolizumab

A post-hoc analysis of KEYNOTE-355 found that patients who discontinued chemotherapy before pembrolizumab maintained progression-free and overall survival comparable to the overall study population, with immune-mediated adverse events that were generally manageable with supportive care. The trade-off under discussion is whether this supports de-escalating the chemotherapy backbone while continuing pembrolizumab in responding PD-L1-high mTNBC, given that immune adverse effects were mostly mild and manageable.

Discussed by: @stolaney1, @TargetedOnc

→ View representative tweet

FDA approves T-DXd for HER2-positive early-stage breast cancer

The FDA approved fam-trastuzumab deruxtecan-nxki for two separate indications in adults with HER2-positive early-stage breast cancer. Clinicians are now considering how moving T-DXd into the early-stage setting will reshape neoadjuvant and post-neoadjuvant sequencing for HER2-positive disease.

Discussed by: @OncologyTimes, @PharmPracNews

→ View representative tweet

🔥 Top Ranked Tweets

OncoAlert @OncoAlert

RT @OncoAlert: Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial

https://t.co/jdD3msifT2

This interim phase 3 trial in China compared trastuzumab rezetecan with pyrotinib plus capecitabine in previously treated HER2-positive metastatic#BreastCancer . In 287 randomized patients, trastuzumab rezetecan significantly📈 improved progression-free survival, with median PFS of 30.6 versus 8.3 months and a hazard ratio of 0.22. It also increased 12-month PFS rates. The regimen showed higher hematologic toxicity but comparable serious adverse event rates, supporting it as a promising new treatment option.

@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H

@nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo
@MarioBalsaMD

🔖 4 ❤️ 19 🔁 14 👁 3,115